Reinventing Biotech’s Business Model: The Photo Gallery

NEXT IMAGE >>
Reinventing Biotech’s Business Model — Plexxikon president Kathy Glaub described the “partner-early/partner-often” strategy that enabled the development-stage company to turn profitable in its last three years, and end up getting acquired by Daiichi Sankyo for $805 million upfront.
Photo by Luke Timmerman

Pages: Page 1, Page 2, Page 3, Page 4, Page 5, Page 6, Page 7, Page 8, Page 9, Page 10, Page 11, Page 12, Page 13, Page 14, Page 15, Page 16, Page 17, Page 18, Page 19, Page 20, Page 21, Page 22, Page 23, Page 24

Author: Luke Timmerman

Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.